Is Gain Therapeutics, Inc. (GANX) Halal?
Shariah Screening — 5 Standards
Based on financial data from December 2024
| Standard | Debt Ratio | Cash Ratio | Receivables | Income | Status |
|---|---|---|---|---|---|
| AAOIFI | 0.6% / 30% | 8.9% / 30% | 0.7% / 30% | N/A | ✓ HALAL |
| DJIM | 0.6% / 33% | 8.9% / 33% | 0.7% / 33% | N/A | ✓ HALAL |
| MSCI | 5.4% / 33% | 85.7% / 33% | 6.3% / 33% | N/A | ✗ NOT HALAL |
| S&P | 0.6% / 33% | 8.9% / 33% | 0.7% / 33% | N/A | ✓ HALAL |
| FTSE | 5.4% / 33% | 85.7% / 33% | 6.3% / 50% | N/A | ✗ NOT HALAL |
Financial Highlights
Profitability
| Gross Margin | 0.0% | |
| Operating Margin | 0.0% | |
| Net Margin | 0.0% | |
| Return on Equity (ROE) | -261.7% | |
| Return on Assets (ROA) | -86.8% |
Cash Flow & Balance Sheet
| Operating Cash Flow | -$19M |
| Free Cash Flow | -$19M |
| Total Debt | $653,015 |
| Debt-to-Equity | 10.2 |
| Current Ratio | 2.5 |
| Total Assets | $12M |
Price & Trading
| Last Close | $1.89 |
| 50-Day MA | $2.13 |
| 200-Day MA | $2.16 |
| Avg Volume | 889K |
| Beta | -0.0 |
|
52-Week Range
$1.41
| |
About Gain Therapeutics, Inc. (GANX)
Gain Therapeutics, Inc., a biotechnology company, develops novel small molecule therapeutics to treat diseases across various therapeutic areas in Switzerland, Spain, the United States, and Australia. Its drug discovery platform Magellan discovers novel allosteric binding sites in a disease; identifies proprietary small molecules that bind these sites to modulate protein function; and treats the underlying cause of the disease. The company's lead drug candidate is GT-02287, which is currently in a Phase 1b study for the treatment of Parkinson's disease with or without a GBA1 mutation. It has various small molecule drug candidates, which are in the discovery, research, and preclinical stages for the treatment of dementia with Lewy bodies, Alzheimer's disease, and Gaucher's disease, lysosomal storage disorders, metabolic disorders, and solid tumors. Gain Therapeutics, Inc. was founded in 2017 and is based in Bethesda, Maryland.
Related Halal Stocks in Healthcare
Frequently Asked Questions
Is Gain Therapeutics, Inc. (GANX) halal to invest in?
Based on our screening using AAOIFI Standard 21 (the strictest methodology), Gain Therapeutics, Inc. is Halal. The company passes all financial ratio thresholds for debt, cash, receivables, and impermissible income. We screen against all 5 major standards: AAOIFI, DJIM, MSCI, S&P, and FTSE.
What is Gain Therapeutics, Inc.'s debt ratio?
Gain Therapeutics, Inc.'s debt ratio is 0.6% under the AAOIFI standard (which uses market capitalization as the denominator). The AAOIFI threshold is 30%. Under MSCI and FTSE (which use total assets as the denominator), the debt ratio is 5.4%.
What are Gain Therapeutics, Inc.'s key financial metrics?
Gain Therapeutics, Inc. has a market capitalization of $70M. Return on equity stands at -261.7%.
How often is the screening data updated?
Our screening data is updated regularly using the latest available financial statements and market data. Stock prices and market caps are refreshed frequently, while financial statements are updated quarterly when companies report earnings.
Disclaimer: HalalStockGuide.com provides Shariah compliance screening for educational and informational purposes only. This is not a fatwa, financial advice, or a recommendation to buy or sell any security. Screening results are based on publicly available financial data and established methodologies. Always consult a qualified Islamic scholar and a licensed financial advisor before making investment decisions.